JP2024513692A - グレムリン１アンタゴニストを使用して疾患を処置する方法 - Google Patents
グレムリン１アンタゴニストを使用して疾患を処置する方法 Download PDFInfo
- Publication number
- JP2024513692A JP2024513692A JP2023555769A JP2023555769A JP2024513692A JP 2024513692 A JP2024513692 A JP 2024513692A JP 2023555769 A JP2023555769 A JP 2023555769A JP 2023555769 A JP2023555769 A JP 2023555769A JP 2024513692 A JP2024513692 A JP 2024513692A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- grem1
- sequence
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/080142 | 2021-03-11 | ||
| CN2021080142 | 2021-03-11 | ||
| CNPCT/CN2022/076516 | 2022-02-16 | ||
| CN2022076516 | 2022-02-16 | ||
| PCT/CN2022/080297 WO2022188856A1 (en) | 2021-03-11 | 2022-03-11 | Method of treating diseases using gremlin1 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513692A true JP2024513692A (ja) | 2024-03-27 |
| JP2024513692A5 JP2024513692A5 (https=) | 2025-03-19 |
| JPWO2022188856A5 JPWO2022188856A5 (https=) | 2025-03-19 |
Family
ID=83226314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555769A Pending JP2024513692A (ja) | 2021-03-11 | 2022-03-11 | グレムリン１アンタゴニストを使用して疾患を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240190950A1 (https=) |
| EP (1) | EP4304646A4 (https=) |
| JP (1) | JP2024513692A (https=) |
| KR (1) | KR20230156936A (https=) |
| CN (1) | CN116940380A (https=) |
| AU (1) | AU2022233762A1 (https=) |
| BR (1) | BR112023018204A2 (https=) |
| CA (1) | CA3213121A1 (https=) |
| MX (1) | MX2023010594A (https=) |
| TW (1) | TW202300527A (https=) |
| WO (1) | WO2022188856A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024504124A (ja) * | 2021-01-18 | 2024-01-30 | スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド | 新規の抗グレムリン１抗体 |
| WO2024213066A1 (en) * | 2023-04-13 | 2024-10-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Combination therapies involving grem1 antagonists for treatment of cancer |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
| CN119746060B (zh) * | 2025-03-07 | 2025-09-16 | 南昌大学第一附属医院 | 一种树突状细胞疫苗制剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6339063B2 (ja) * | 2012-03-15 | 2018-06-06 | エスエヌユー アールアンドディービー ファウンデーション | グレムリン−１に対する抗体 |
| ES2898620T3 (es) * | 2013-03-14 | 2022-03-08 | Regeneron Pharma | Anticuerpos humanos contra GREM 1 |
| US10844051B2 (en) * | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| PL3806898T3 (pl) * | 2018-06-18 | 2026-02-23 | UCB Biopharma SRL | Antagonista gremlin-1 do zastosowania w leczeniu nowotworu |
| JP2024504124A (ja) * | 2021-01-18 | 2024-01-30 | スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド | 新規の抗グレムリン１抗体 |
-
2022
- 2022-03-11 BR BR112023018204A patent/BR112023018204A2/pt unknown
- 2022-03-11 MX MX2023010594A patent/MX2023010594A/es unknown
- 2022-03-11 CN CN202280020454.8A patent/CN116940380A/zh active Pending
- 2022-03-11 KR KR1020237034659A patent/KR20230156936A/ko active Pending
- 2022-03-11 WO PCT/CN2022/080297 patent/WO2022188856A1/en not_active Ceased
- 2022-03-11 EP EP22766378.8A patent/EP4304646A4/en active Pending
- 2022-03-11 TW TW111109016A patent/TW202300527A/zh unknown
- 2022-03-11 JP JP2023555769A patent/JP2024513692A/ja active Pending
- 2022-03-11 CA CA3213121A patent/CA3213121A1/en active Pending
- 2022-03-11 AU AU2022233762A patent/AU2022233762A1/en active Pending
- 2022-03-11 US US18/549,928 patent/US20240190950A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023018204A2 (pt) | 2023-10-24 |
| US20240190950A1 (en) | 2024-06-13 |
| KR20230156936A (ko) | 2023-11-15 |
| CN116940380A (zh) | 2023-10-24 |
| TW202300527A (zh) | 2023-01-01 |
| WO2022188856A1 (en) | 2022-09-15 |
| EP4304646A4 (en) | 2025-05-28 |
| EP4304646A1 (en) | 2024-01-17 |
| CA3213121A1 (en) | 2022-09-15 |
| MX2023010594A (es) | 2023-09-25 |
| AU2022233762A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240011098A1 (en) | Diagnostic and therapeutic methods for cancer | |
| JP7212902B2 (ja) | 疾患および障害の処置においてレナラーゼを制御する組成物および方法 | |
| WO2022188856A1 (en) | Method of treating diseases using gremlin1 antagonists | |
| AU2015313268B2 (en) | Cancer-cell-specific antibody, anticancer agent, and cancer testing method | |
| JP2022058699A (ja) | 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体 | |
| CN110546277A (zh) | 用于癌症的诊断和治疗方法 | |
| CN110650752A (zh) | 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体 | |
| KR102644658B1 (ko) | 모노클로날 항체 항-fgfr4 | |
| JP2023551602A (ja) | Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット | |
| CN112912403A (zh) | 治疗肿瘤的方法 | |
| CN113891748A (zh) | 治疗肿瘤的方法 | |
| CN113396230A (zh) | 癌症的诊断和治疗方法 | |
| CN112292151A (zh) | 抗pd-1抗体在制备治疗实体瘤的药物中的用途 | |
| KR20210063330A (ko) | 방광암에 대한 치료 및 진단 방법 | |
| CN110139661A (zh) | Igfb3及其受体相关疾病的治疗 | |
| CN119156228A (zh) | 抗tigit抗体及其用途 | |
| WO2011007853A1 (ja) | 癌特異的アイソフォームに対するモノクローナル抗体 | |
| US20180134788A1 (en) | Methods and Pharmaceutical Compositions (NTSR1 Inhibitors) for the Treatment of Hepatocellular Carcinomas | |
| RU2853818C9 (ru) | Способ лечения заболеваний с применением антагонистов GREMLIN1 | |
| RU2853818C1 (ru) | Способ лечения заболеваний с применением антагонистов GREMLIN1 | |
| EP4115904A2 (en) | Anti-rspo3 antibodies | |
| US20240425604A1 (en) | Treatment of immune checkpoint inhibitor-treated cancers with high egfr expression using an antibody that binds at least egfr | |
| HK40094175A (zh) | 使用grem1拮抗剂治疗疾病的方法 | |
| WO2023165618A1 (en) | Methods for treating cancer | |
| HK40055955A (en) | Diagnostic and therapeutic methods for cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250311 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250311 |